Table 1.
All | GOLD grade
|
ANOVA P-value | |||
---|---|---|---|---|---|
2 | 3 | 4 | |||
N | 139 | 46 | 56 | 37 | |
Sex, M/F | 134/5 | 46/0 | 53/3 | 35/2 | |
Age (yr) | 63±8 | 63±8 | 63±7 | 60±7 | NS |
BMI (m/kg2) | 25±4 | 24±4 | 26±3 | 24±4 | NS |
FVC (% pred) | 72±18 | 82±14 | 71±17* | 60±17*,≠ | <0.001 |
FEV1 (L) | 1.3±0.6 | 1.9±0.5 | 1.2±0.2* | 0.7±0.2*,≠ | <0.001 |
FEV1 (% pred) | 41±16 | 59±7 | 39±6* | 20±4*,≠ | <0.001 |
FEV1/FVC (%) | 40±15 | 52±8 | 41±14* | 25±8*,≠ | <0.001 |
TLC (% pred) | 116±21 | 113±17 | 112±22 | 124±22≠ | 0.004 |
RV (% pred) | 200±75 | 156±44 | 191±69* | 266±68*,≠ | <0.001 |
IC (% pred) | 62±18 | 76±16 | 63±16* | 47±12*,≠ | <0.001 |
RV/TLC (%) | 61±11 | 52±8 | 59±9* | 71±8*,≠ | <0.001 |
IC/TLC ratio | 0.26±0.07 | 0.32±0.06 | 0.27±0.07* | 0.18±0.05*,≠ | <0.001 |
DLco (% pred) | 57±25 | 72±23 | 59±21* | 36±15*,≠ | <0.001 |
PaO2 (mmHg) | 69±12 | 77±10 | 68±11* | 62±11*,≠ | <0.001 |
PaCO2 (mmHg) | 40±6 | 37±4 | 41±6* | 45±7*,≠ | <0.001 |
AaPO2 (mmHg) | 32±10 | 30±11 | 32±9 | 34±10 | NS |
Notes: Data are presented as means ± standard deviation. Significant differences within each variable are indicated as:
different from GOLD grade 2;
different from GOLD grade 3.
Abbreviations: AaPO2, alveolar–arterial oxygen partial pressure difference; ANOVA, analysis of variance; BMI, body mass index; DLco, diffusing capacity for carbon dioxide; FEV1, post-bronchodilator forced expiratory volume in 1 second; FEV1/FVC, post-bronchodilator forced expiratory volume in 1 second/post-bronchodilator forced vital capacity; FVC, post-bronchodilator forced vital capacity; GOLD, Global Initiative for Chronic Obstructive Pulmonary Disease; IC, inspiratory capacity; IC/TLC, inspiratory capacity/total lung capacity ratio; M/F, male/female; NS, not significant; PaCO2, partial pressure of arterial carbon dioxide; PaO2, partial pressure of arterial oxygen; pred, predicted; RV, residual volume; RV/TLC, residual volume/total lung capacity ratio; TLC, total lung capacity.